Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growth
An opportunity to talk directly to the companies and personally put forward your questions
The chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutions

 

WHO SHOULD ATTEND?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Wednesday 26th November 2014

Venue:

Novotel Tower Bridge, 10 Pepys Street, London  EC3N 2NR

Evening timings:

18:00 - 18:30 Registration and coffee

18:30 - 20:30 Presentations

20:30 - 21:30  Drinks reception and canapés

 

Attendance is complimentary, but spaces are limited. Register now to secure your place!

 

Avation (AIM: AVAP)
Avation PLC is a specialist commercial passenger aircraft leasing company managing a fleet of 28 aircraft which it leases to airlines across the world. Our customers include Virgin Australia, Thomas Cook, Condor, Fiji Airways and UNI Air. Avation also has a subsidiary that supplies aircraft parts and spares to a range of operators, internationally.

 

Speaker: Richard Wolanski – Finance Director



 

Sphere Medical [AIM: SPHR]

Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs.

Speaker: Dr Wolfgang Rencken, Chief Executive Officer 

VALIRX (AIM:VAL)

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Speaker: Satu Vainikka, CEO

Supported by:                                                                                                      Event Sponsor:





 

DRESS CODE: Business attire 

 

Avation added